Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies-Reference-Cited by-同舟云学术

Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies

Published:2019-10-01 Issue:6 Volume:22 Page:919-927
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Sakakida T.^ORCID,Ishikawa T.^ORCID,Chihara Y.,Harita S.,Uchino J.,Tabuchi Y.,Komori S.,Asai J.,Narukawa T.,Arai A.,Tsunezuka H.,Kosuga T.,Konishi H.,Moriguchi M.,Yasuda H.,Hongo F.,Inoue M.,Hirano S.,Ukimura O.,Itoh Y.,Taguchi T.,Takayama K.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-019-02214-8.pdf

Reference33 articles.

1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.

2. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.

3. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.

4. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67.

5. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311–9.

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease;European Journal of Cancer;2024-08

2. Sicca syndrome/Sjögren’s disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management;Expert Review of Clinical Immunology;2024-06-25

3. Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma;Journal for ImmunoTherapy of Cancer;2024-06

4. Immune Checkpoint Therapy–Induced Lupus Nephritis;Kidney International Reports;2024-05

5. The Current and Future of Biomarkers of Immune Related Adverse Events;Rheumatic Disease Clinics of North America;2024-05